The FDA on May 8, 2026, approved BIZENGRI® for adults with advanced, unresectable or metastatic cholangiocarcinoma harboring a NeuReGulin 1 (NRG1) gene fusion with disease progression on or after prior systemic therapy. NRG1-fusion positive cholangiocarcinoma is an extremely rare, life-threatening malignancy. BIZENGRI® is a product of Partner Therapeutics, Inc.
Bottom Ad
Advertisement
Subscribe
